Increased SST 2 Expression on Pulmonary Neuroendocrine Tumor Cells by Epigenetic Drug Treatment with Histone Deacetylase Inhibitors

Research output: Contribution to journalMeeting AbstractAcademicpeer-review

6 Citations (Scopus)

Abstract

Aim/Introduction: Our aim is to increase the expression of somatostatin type-2 receptors (SST2) on the pulmonary neuroendocrine tumor (NET) cell line NCI-H727 by using epigenetic drugs. We tested the effect of six histone deacetylase inhibitors (HDACis), aiming to promote the euchromatin state supporting SST2 gene transcription. This approach may possibly open up opportunities for NET patients with insufficient tumoral SST2, thereby increasing the number of patients eligible for SST2-targeted therapies such as peptide receptor radionuclide therapy (PRRT). We also compared our results with similar studies performed in the pancreatic NET cell line BON-1.
Original languageEnglish
Article numberOP-830
Pages (from-to)S411-S412
Number of pages2
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume47
Issue numberSuppl 1
DOIs
Publication statusPublished - Sept 2020
Event33rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM) -
Duration: 22 Oct 202030 Oct 2020

Fingerprint

Dive into the research topics of 'Increased SST 2 Expression on Pulmonary Neuroendocrine Tumor Cells by Epigenetic Drug Treatment with Histone Deacetylase Inhibitors'. Together they form a unique fingerprint.

Cite this